IDH mutation occurs in the early stage of glioma development [139] and alters enzyme function to produce the oncometabolite 2-hydroxyglutaric acid (2-HG) [140], which is thought to cause glioma-specific methylation of CpG islands (G-CIMP), which is tumorigenic [141]. Here, IDH1 is linked to central nervous system cancer.